杜皮鲁玛
特应性皮炎
间充质干细胞
细胞外小泡
免疫学
医学
干细胞
癌症研究
细胞外
生物
细胞因子
单克隆抗体
体内
干细胞疗法
免疫系统
胞外囊泡
免疫疗法
抗体
干细胞因子
作者
Doil Park,Joo Ho Kim,Hyeock Yang,Yeeun Ji,Jaein Yoo,Jieun Kim,Oh Young Bang
标识
DOI:10.1186/s13287-025-04649-z
摘要
Abstract Background Atopic dermatitis (AD) is a chronic inflammatory skin disease primarily treated with corticosteroids and dupilumab, a monoclonal antibody targeting interleukin (IL)-4 and IL-13. Mesenchymal stem cell-derived extracellular vesicles (MSC-EVs) are promising alternatives owing to their anti-inflammatory properties. This study compared the therapeutic effects of dupilumab and MSC-EVs in a murine model of AD. We employed clinical, serological, and histological analyses to assess the efficacy of these treatments and investigated their mechanisms in vitro and in vivo. Methods We generated Wharton’s jelly MSC-EVs using a 3D microwell-based platform and evaluated their effects in an AD mouse model. AD was induced by repeated application of 2,4-dinitrochlorobenzene (DNCB) and sodium dodecyl sulfate (SDS). The mice were randomly divided into four groups: healthy (normal), placebo (DNCB + SDS), EV (6 × 108 particles once), and dupilumab (25 mg/kg biweekly) groups. Dupilumab and EVs were injected subcutaneously into the dorsal skin of the mice. Dermatitis scores, serum inflammatory markers, and histological analyses were performed to evaluate disease severity and changes at the tissue level. Additionally, tumor necrosis factor (TNF)-α-induced HaCaT cells were utilized for in vitro experiments to investigate the molecular mechanisms of MSC-EV therapy. Results EVs and dupilumab improved the clinical dermatitis score, reduced epidermal thickness, and promoted restoration of the skin barrier in mice with AD. Treatments decreased T helper (Th)2 and pro-inflammatory cytokines, but EVs, unlike dupilumab, effectively suppressed Th1 and Th22 cytokines. EVs suppress Th1 activation through the AKT/NF-κB pathway via microRNA-146a. Conclusions MSC-EVs offer a novel cell-free therapy for AD, demonstrating comparable or superior efficacy to dupilumab, with broader immunomodulatory effects and the advantage of a single-dose administration.
科研通智能强力驱动
Strongly Powered by AbleSci AI